Lobbyists Urge Scientists To Get Involved on the Hill

The lobbyist credited his client. The client credited his lobbyist. Both praised scientists and legislators on the brink of an historic vote that would put the National Institutes of Health on the path to doubling its budget in five years. Congress, as of press time for The Scientist, was poised to pass a $500 billion legislative package that includes a $2 billion increase for the National Institutes of Health. The agency received $13.648 billion for 1998. Prior to the vote on the "omnibus" spe

Written byPaul Smaglik
| 9 min read

Register for free to listen to this article
Listen with Speechify
0:00
9:00
Share

The lobbyist credited his client. The client credited his lobbyist. Both praised scientists and legislators on the brink of an historic vote that would put the National Institutes of Health on the path to doubling its budget in five years. Congress, as of press time for The Scientist, was poised to pass a $500 billion legislative package that includes a $2 billion increase for the National Institutes of Health. The agency received $13.648 billion for 1998. Prior to the vote on the "omnibus" spending bill, the Senate appropriations committee requested $15.6 billion for the agency--$819 million more than requested by President Bill Clinton in February (B. Agnew, The Scientist, 12[6]:1, March 16, 1998).

That vote represents the success of science advocacy--a complex network of registered lobbyists, informal advocates, scientists active on Capitol Hill, and philanthropists who help fund the campaign. While that network may have made a difference in this ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies